Abstract | OBJECTIVES: METHODS: Retrospective medical record review of 180 patients who were started on etanercept between December 1998 and April 2000 at an academic medical center. RESULTS: CONCLUSIONS: The majority of the studied patients tolerated etanercept for longer than 6 months. Many of these patients were able to subsequently taper or even discontinue corticosteroid and methotrexate therapy. Serious infections occurred in this patient population. Our results underscore the value of long-term observation under the conditions of clinical practice beyond controlled clinical trials.
|
Authors | Kristine Phillips, M Elaine Husni, Elizabeth W Karlson, Jonathan S Coblyn |
Journal | Arthritis and rheumatism
(Arthritis Rheum)
Vol. 47
Issue 1
Pg. 17-21
(Feb 2002)
ISSN: 0004-3591 [Print] United States |
PMID | 11932873
(Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antirheumatic Agents
- Immunoglobulin G
- Immunologic Factors
- Receptors, Tumor Necrosis Factor
- Etanercept
- Prednisone
- Methotrexate
|
Topics |
- Academic Medical Centers
- Antirheumatic Agents
(therapeutic use)
- Etanercept
- Female
- Humans
- Immunoglobulin G
(adverse effects, therapeutic use)
- Immunologic Factors
(adverse effects, therapeutic use)
- Infections
(etiology)
- Male
- Massachusetts
- Methotrexate
(therapeutic use)
- Middle Aged
- Prednisone
(therapeutic use)
- Receptors, Tumor Necrosis Factor
(therapeutic use)
- Rheumatic Diseases
(complications, drug therapy)
|